Compounds with a graded row

Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.

1. Neuropeptide Y

   human RCT Direct outcome In registered trials

   Who was studied

   adults with PTSD (CAPS >= 50), n=26 enrolled / 24 completed, 67% female, single intranasal dose per session; not a diagnosed anxiety-disorder population

   A phase Ib double-blind, placebo-controlled crossover dose-ranging study measured the Beck Anxiety Inventory and STAI-State after a single intranasal dose of 1.4-9.6 mg during a trauma-script provocation; higher doses were associated with lower BAI scores, while STAI-State and IES-R showed non-significant trends. The population was PTSD, not generalised or social anxiety disorder, and a single dose in a provocation paradigm is not a treatment course; no repeated-dosing trial is on file.

   Source PubMed Central 1 primary source read for this row

2. Selank

   human RCT Direct outcome Approved for this condition

   Who was studied

   patients with generalised anxiety disorder or neurasthenia, n=62 (30 selank, 32 medazepam comparator), adolescent to middle-aged, sex not reported; treatment duration not reported in the abstract

   A comparator-controlled trial measured anxiety directly with the Hamilton anxiety scale, the Zung scale and CGI, and reported anxiolytic effect similar to medazepam. Selank is registered as an anxiolytic in the Russian Federation only; there is no FDA or EMA approval for any condition. The report is published in Russian in Zh Nevrol Psikhiatr Im S S Korsakova and only the English abstract could be read, so blinding, randomisation method and trial duration are not on file; there is no placebo arm.

   Source PubMed 1 primary source read for this row

3. Oxytocin

   human RCT Mechanistic only Not approved for this condition

   Who was studied

   men with generalised social anxiety disorder, n=17, plus 18 healthy male control participants; single dose, sessions at least 7 days apart

   Recorded, and not evidence for this condition

   A randomised, double-blind, placebo-controlled crossover study gave a single 24 IU intranasal dose and measured amygdala functional connectivity to fearful faces on fMRI. Anxiety scales (LSAS, BAI, STAI) were used only to characterise participants at baseline, not as treatment endpoints, so no study here measured whether anxiety symptoms changed; the link from an imaging signal to symptom relief is an argument, not a result. Oxytocin is approved for obstetric use, not for anxiety, in any jurisdiction on file.

   Source PubMed Central 1 primary source read for this row

Checked, and nothing recorded

5 compounds were checked against anxiety and produced no gradeable row.

• DSIP — checked, no row on file
• Epitalon — checked, no row on file
• Nociceptin — checked, no row on file
• PEA — checked, no row on file
• Semax — checked, no row on file

A compound is here because someone looked and the sources did not support a row — not because nobody looked. Under the rubric, uncertainty resolves to no row, and a row resting on a vendor page or a clinic blog is worse than no row at all.